KalVista Pharmaceuticals (KALV) COO awarded 49,000 RSUs in equity grant

Rhea-AI Filing Summary

KalVista Pharmaceuticals, Inc. reported that its Chief Operations Officer, Arif Bilal, received a grant of 49,000 restricted stock units (RSUs) on January 16, 2026. Each RSU represents a contingent right to receive 1 share of KalVista common stock upon settlement for no cash consideration.

The RSUs vest in equal installments over four years. Specifically, 1/16 of the total RSUs will vest on each quarterly anniversary of the vesting commencement date, starting May 22, 2026, as long as Bilal’s service with the company does not terminate. Following this grant, he beneficially owns 49,000 RSUs directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Arif Bilal

Role Chief Operations Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	49,000	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 49,000 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arif Bilal

(Last) (First) (Middle)

C/O KALVISTA PHARMACEUTICALS, INC.

200 CROSSING BOULEVARD

(Street)

FRAMINGHAM MA 01702

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KalVista Pharmaceuticals, Inc. [ KALV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operations Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/16/2026		A		49,000		(2)	(2)	Common Stock	49,000	$0	49,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate.

	/s/ Benjamin L. Palleiko, Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did KalVista Pharmaceuticals (KALV) report for Arif Bilal?

KalVista Pharmaceuticals reported that Chief Operations Officer Arif Bilal was granted 49,000 restricted stock units (RSUs) on January 16, 2026.

How many KalVista (KALV) shares are covered by Arif Bilal’s RSU grant?

The grant covers 49,000 restricted stock units, each representing a contingent right to receive 1 share of KalVista common stock upon settlement.

What is the vesting schedule for Arif Bilal’s 49,000 KalVista (KALV) RSUs?

The RSUs vest as follows: 1/16 of the total vests on each quarterly anniversary of the vesting commencement date, beginning on May 22, 2026, while his service continues.

Does Arif Bilal pay anything for the KalVista (KALV) RSUs?

No. Each RSU represents a right to receive 1 share of common stock for no consideration upon settlement.

How many KalVista (KALV) RSUs does Arif Bilal beneficially own after this transaction?

After this grant, Arif Bilal beneficially owns 49,000 restricted stock units, held with direct ownership.

What role does Arif Bilal hold at KalVista Pharmaceuticals (KALV)?

Arif Bilal serves as Chief Operations Officer of KalVista Pharmaceuticals, Inc.